How Do You Manage Inverse Psoriasis?
Title: How Do You Manage Inverse Psoriasis?Category: Diseases and ConditionsCreated: 6/7/2022 12:00:00 AMLast Editorial Review: 6/7/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 7, 2022 Category: Dermatology Source Type: news

The Biological Basis of Disease Recurrence in Psoriasis The Biological Basis of Disease Recurrence in Psoriasis
This review explores the immunopathology of psoriasis lesion recurrence, highlighting emerging data on the concept of a localized immunological ' memory ' that persists in resolved skin.The British Journal of Dermatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 6, 2022 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news

Where Does Psoriasis Usually Start?
Title: Where Does Psoriasis Usually Start?Category: Diseases and ConditionsCreated: 6/3/2022 12:00:00 AMLast Editorial Review: 6/3/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 3, 2022 Category: Dermatology Source Type: news

What Is the Most Severe Form of Psoriasis?
Title: What Is the Most Severe Form of Psoriasis?Category: Diseases and ConditionsCreated: 6/3/2022 12:00:00 AMLast Editorial Review: 6/3/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 3, 2022 Category: Dermatology Source Type: news

Serum Brodalumab Level Linked With Psoriasis Treatment Outcomes Serum Brodalumab Level Linked With Psoriasis Treatment Outcomes
Subquantifiable brodalumab levels were associated with a lack of response after 12 weeks, in the retrospective study.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 2, 2022 Category: Dermatology Tags: Dermatology News Source Type: news

Picture of Psoriasis Vulgaris Palms
Title: Picture of Psoriasis Vulgaris PalmsCategory: ImagesCreated: 12/16/2010 5:36:00 PMLast Editorial Review: 6/2/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 2, 2022 Category: Dermatology Source Type: news

What Is Generalized Pustular Psoriasis?
Title: What Is Generalized Pustular Psoriasis?Category: Diseases and ConditionsCreated: 6/2/2022 12:00:00 AMLast Editorial Review: 6/2/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 2, 2022 Category: Dermatology Source Type: news

Psoriasis Tied to Higher Risk for Nonalcoholic Fatty Liver Disease
WEDNESDAY, June 1, 2022 -- Psoriasis is associated with nonalcoholic fatty liver disease (NAFLD) in a U.S. outpatient population, according to a study published May 25 in JAMA Dermatology. Zhijie Ruan, M.Med., from the First Affiliated Hospital of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 1, 2022 Category: Pharmaceuticals Source Type: news

Episode 4: When Should Phototherapy Be Used for Psoriasis? Episode 4: When Should Phototherapy Be Used for Psoriasis?
Dr Joel Gelfand talks with Dr Steven Feldman about why phototherapy is an important tool for treating psoriasis, with insights on who can benefit, how to approach patients about it, and tanning bed use.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 1, 2022 Category: Consumer Health News Tags: Dermatology InDiscussion Source Type: news

New Data Show Patients Treated with First-in-Class TREMFYA ® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years
SPRING HOUSE, PENNSYLVANIA, June 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with TREMFYA® (guselkumab) achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis,a dactylitis,b spinal pain and disease severityc endpoints – irrespective of baseline characteristics.1 Further analyses showed TREMFYA also provided patients with sustained improvements in measures of health-related quality of life (HRQoL), including fatigue, pain...
Source: Johnson and Johnson - June 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Psoriasis Linked With Higher Risk for Fatty Liver Disease Psoriasis Linked With Higher Risk for Fatty Liver Disease
Psoriasis is linked with a higher risk for nonalcoholic fatty liver disease in US outpatients, a recent study found.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 31, 2022 Category: Gastroenterology Tags: Dermatology News Source Type: news

Featured review: Which medicines, taken by mouth or injected, work best to treat a skin condition called plaque psoriasis?
Thursday, May 26, 2022 (Source: Cochrane News and Events)
Source: Cochrane News and Events - May 26, 2022 Category: Information Technology Authors: Lydia Parsonson Source Type: news

What Is Chronic Plaque Psoriasis?
Title: What Is Chronic Plaque Psoriasis?Category: Diseases and ConditionsCreated: 5/26/2022 12:00:00 AMLast Editorial Review: 5/26/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - May 26, 2022 Category: Dermatology Source Type: news

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

FDA Approves Topical Tapinarof for Plaque Psoriasis FDA Approves Topical Tapinarof for Plaque Psoriasis
Tapinarof is an aryl hydrocarbon receptor agonist and is the first FDA-approved steroid-free topical medication in this class, according to the manufacturer.FDA Approvals (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - May 24, 2022 Category: Internal Medicine Tags: Dermatology News Alert Source Type: news